The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 986-990

  Ku, Hei Young ^a   Ahn, Hee Jeong ^a   Seo, Kyung Ah ^a   Kim, Hyunmi ^a   Oh, Minkyung ^c   Soo, Kyung Bae ^c   Shin, Jae Gook ^a,b,c   Shon, Ji Hong ^a,c   Liu, Kwang Hyeon ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; N DEMETHYLASE; SILDENAFIL; UDENAFIL; VARDENAFIL;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DRUG CLEARANCE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; CYTOCHROME P-450 CYP3A; HUMANS; IMIDAZOLES; MICROSOMES, LIVER; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; PYRIMIDINES; RECOMBINANT PROTEINS; SULFONES; TRIAZINES;

EID: 44149107346     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.020099     Document Type: Article

References (33)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-10395.
2. Bischoff E (2004) Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 16 (Suppl 1):S34-S37.
3. Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, and Zhang L (2002) Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 30:1344-1351.
4. Dennison JB, Jones DR, Renbarger JL, and Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563.
5. Emoto C and Iwasaki K (2006) Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36:219-233.
6. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
7. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
8. Gupta M, Kovar A, and Meibohm B (2005) The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45:987-1003.
9. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
10. Hyland R, Roe EG, Jones BC, and Smith DA (2001) Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 51:239-248.
11. Ji HY, Lee HW, Kim HH, Kim DS, Yoo M, Kim WB, and Lee HS (2004) Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Xenobiotica 34:973-982.
12. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, and Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374-1381.
13. Keating GM and Scott LJ (2003) Vardenafil: a review of its use in erectile dysfunction. Drugs 63:2673-2703.
14. Kim H, Seo KA, Kim H, Lee HS, Lee CH, Shin JG, and Liu KH (2007) Enzyme kinetic study of a new cardioprotective agent, KR-32570 using human liver microsomes and recombinant CYP isoforms. Arch Pharmacol Res 30:469-474.
15. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, and Shin JG (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651-2658.
16. Kivistö KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, and Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523-525.
17. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, Horstmann R, and Engelmann R (2001) Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 19:32-39.
18. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
20. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
21. Mehrotra N, Gupta M, Kovar A, and Meibohm B (2007) The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 19:253-264.
22. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
23. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, and Shin JG (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 79:590-599.
24. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938-944.
25. Rajagopalan P, Mazzu A, Xia C, Dawkins R, and Sundaresan P (2003) Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 43:260-267.
26. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, and Roger M (2005) CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33:884-887.
27. Schrag ML and Wienkers LC (2001) Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab Dispos 29:70-75.
28. Shim HJ, Kim YC, Park KJ, Kim DS, Kwon JW, Kim WB, and Lee MG (2003) Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci 92:2185-2195.
29. Warrington JS, Shader RI, von Moltke LL, and Greenblatt DJ (2000) In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28:392-397.
30. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
31. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
32. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
33. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.